Safety
delirium, pneumonitis, death, confusion, neutropenia, febrile neutropenia, abdominal pain, leukopenia, thrombocytopenia, anemia, hyperglycemia, lymphopenia, mucositis, thoracic disease, leukocytosis, anorexia
PNEUMONITIS, DISEASE PROGRESSION, ALEUKOCYTOSIS, NEUTROPENIA, FEBRILE NEUTROPENIA, LEUKOPENIA, ADVERSE EVENTS, THROMBOCYTOPENIA, ANEMIA, HYPERGLYCEMIA, LYMPHOPENIA, MUCOSITIS, THORACIC DISEASE, ANOREXIA
Safety was evaluated in 15 patients. All 15 patients had at least 1 grade 3 AE, while 9 patients had a grade 3 or higher AE related to the study drug. Grade 3–4 treatment‐related non‐hematological AEs included mucositis (3), hyperglycemia (2), anorexia (1), confusion (1), delirium (1), abdominal pain (1), bilirubin increase (1), febrile neutropenia (1), fibrinogen decrease (1), thoracic disease (1), and pneumonitis (1). Two patients suffered G5 death shortly after coming off the protocol due to disease progression. Grade 3–4 hematological AEs, at least possibly related to treatment, included anemia (4), lymphopenia (2), leukopenia (2), leukocytosis (1), thrombocytopenia (4), and neutropenia (1) (Table Treatment‐related adverse events on study.